Injuries prompt recall of Medtronic insulin sets:
This article was originally published in Clinica
Medtronic is recalling its Quick-set Plus insulin infusion sets for diabetics in the US after a number of serious injuries and hospitalisations. Bending of the cannula and accidental disconnection at the insertion site causing interruption to the flow of insulin have been reported. The recall has been defined as class I by the FDA, meaning there is "a reasonable probability that the use of the product will cause serious adverse health consequences or death". In March, the company gave customers a tips guide for using the device, and offered replacement sets on request, following increased number of complaints. Medtronic has stopped selling Quick-set Plus sets.
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.